FIELD: pharmaceuticals.
SUBSTANCE: invention refers to pharmaceutical industry, particularly to production of new haemostatic agents based on biological raw materials. Ointment contains the following ratio of components, wt%: chitosan succinate – 1.25; lecinol (lecithin) – 20.63; marigold extract – 19.67; glycerol – 6.88; lidocaine – 5.0, dioxidine – 3.13; preservative – 0.05, distilled water – 43.39.
EFFECT: creation of haemostatic anti-inflammatory ointment.
1 cl, 1 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
LOCAL HAEMOSTATIC ANTIBACTERIAL AGENT | 2021 |
|
RU2776015C1 |
LOCAL HEMOSTATIC AGENT | 2013 |
|
RU2519220C1 |
LOCAL HEMOSTATIC AGENT | 2023 |
|
RU2807892C1 |
MEDICINAL MULTILAYER BANDAGE AND ARTICLES BASED ON SUCH BANDAGE | 2002 |
|
RU2240140C2 |
AGENT FOR WOUNDS, BURNS AND INFECTIOUS INFLAMMATORY DISEASES OF SKIN, APPENDAGES AND MUCOUS MEMBRANES | 2010 |
|
RU2452475C2 |
HAEMOSTATIC AGENT BASED ON POLYVINYLPYRROLIDONE AND METHODS FOR PREPARING ITS PHARMACOLOGICAL FORMS | 2018 |
|
RU2705812C1 |
ANALGESIC, HAEMOSTATIC AND WOUND HEALING AGENT | 2009 |
|
RU2409371C1 |
COMPOSITION FOR WOUND TREATMENT AND PRODUCTS ON ITS BASIS | 2011 |
|
RU2467767C1 |
MEDICINAL MATERIAL AND PRODUCTS BASED UPON THIS MATERIAL | 2002 |
|
RU2249467C2 |
HEMOSTATIC SPONGE (VERSIONS) | 2016 |
|
RU2627855C1 |
Authors
Dates
2019-07-12—Published
2019-04-24—Filed